CSPC Pharmaceutical Group Limited (CVG) - Net Assets

Latest as of December 2025: €34.55 Billion EUR ≈ $40.39 Billion USD

Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CVG) has net assets worth €34.55 Billion EUR (≈ $40.39 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€46.70 Billion ≈ $54.59 Billion USD) and total liabilities (€12.15 Billion ≈ $14.20 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CVG tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€34.55 Billion
% of Total Assets	73.99%
Annual Growth Rate	13.45%
5-Year Change	28.78%
10-Year Change	278.62%
Growth Volatility	11.54

CSPC Pharmaceutical Group Limited - Net Assets Trend (2013–2025)

This chart illustrates how CSPC Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. See CSPC Pharmaceutical Group Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for CSPC Pharmaceutical Group Limited (2013–2025)

The table below shows the annual net assets of CSPC Pharmaceutical Group Limited from 2013 to 2025. For live valuation and market cap data, see market cap of CSPC Pharmaceutical Group Limited.

Year	Net Assets	Change
2025-12-31	€34.55 Billion ≈ $40.39 Billion	+2.02%
2024-12-31	€33.87 Billion ≈ $39.59 Billion	-3.29%
2023-12-31	€35.02 Billion ≈ $40.94 Billion	+10.67%
2022-12-31	€31.64 Billion ≈ $36.99 Billion	+17.94%
2021-12-31	€26.83 Billion ≈ $31.37 Billion	+16.13%
2020-12-31	€23.10 Billion ≈ $27.01 Billion	+18.36%
2019-12-31	€19.52 Billion ≈ $22.82 Billion	+25.93%
2018-12-31	€15.50 Billion ≈ $18.12 Billion	+20.38%
2017-12-31	€12.87 Billion ≈ $15.05 Billion	+41.09%
2016-12-31	€9.13 Billion ≈ $10.67 Billion	+3.55%
2015-12-31	€8.81 Billion ≈ $10.30 Billion	+8.11%
2014-12-31	€8.15 Billion ≈ $9.53 Billion	+7.30%
2013-12-31	€7.60 Billion ≈ $8.88 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to CSPC Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 800.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	€24.48 Billion	73.77%
Other Components	€8.70 Billion	26.23%
Total Equity	€33.18 Billion	100.00%

CSPC Pharmaceutical Group Limited Competitors by Market Cap

The table below lists competitors of CSPC Pharmaceutical Group Limited ranked by their market capitalization.

Company	Market Cap
D'Ieteren Group SA BR:DIE	$9.80 Billion
Smithfield Foods, Inc. Common Stock NASDAQ:SFD	$9.80 Billion
James Hardie Industries plc F:JHA	$9.80 Billion
Gildan Activewear Inc. TO:GIL	$9.81 Billion
Yangzhou Yangjie Electronic Technology Co Ltd SHE:300373	$9.79 Billion
Allison Transmission Holdings Inc NYSE:ALSN	$9.78 Billion
Barito Pacific Tbk JK:BRPT	$9.77 Billion
China Eastern Airlines Corp Ltd SHG:600115	$9.77 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CSPC Pharmaceutical Group Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 32,264,695,000 to 33,178,167,000, a change of 913,472,000 (2.8%).
Net income of 3,882,108,000 contributed positively to equity growth.
Dividend payments of 2,497,337,000 reduced retained earnings.
Share repurchases of 277,633,000 reduced equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€3.88 Billion	+11.7%
Dividends Paid	€2.50 Billion	-7.53%
Share Repurchases	€277.63 Million	-0.84%
Other Changes	€-75.73 Million	-0.23%
Total Change	€-	2.83%

Book Value vs Market Value Analysis

This analysis compares CSPC Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.25x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 0.69x to 0.25x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€1.07	€0.73	x
2018-12-31	€1.25	€0.73	x
2019-12-31	€1.54	€0.73	x
2020-12-31	€1.87	€0.73	x
2021-12-31	€2.17	€0.73	x
2022-12-31	€2.53	€0.73	x
2023-12-31	€2.79	€0.73	x
2024-12-31	€2.81	€0.73	x
2025-12-31	€2.91	€0.73	x

Capital Efficiency Dashboard

This dashboard shows how efficiently CSPC Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 11.70%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.93%
• Asset Turnover: 0.56x
• Equity Multiplier: 1.41x
Recent ROE (11.70%) is below the historical average (18.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	13.05%	9.78%	0.82x	1.64x	€227.49 Million
2014	15.70%	11.58%	0.88x	1.55x	€460.53 Million
2015	19.06%	14.62%	0.84x	1.55x	€791.47 Million
2016	20.78%	16.98%	0.84x	1.46x	€976.07 Million
2017	18.08%	17.92%	0.72x	1.41x	€1.03 Billion
2018	21.37%	17.38%	0.80x	1.54x	€1.71 Billion
2019	20.12%	16.80%	0.84x	1.43x	€1.87 Billion
2020	23.10%	20.69%	0.83x	1.35x	€2.93 Billion
2021	21.57%	20.11%	0.80x	1.34x	€3.01 Billion
2022	20.17%	19.69%	0.74x	1.38x	€3.07 Billion
2023	17.69%	18.68%	0.68x	1.39x	€2.55 Billion
2024	13.41%	14.92%	0.65x	1.38x	€1.10 Billion
2025	11.70%	14.93%	0.56x	1.41x	€564.29 Million

Industry Comparison

This section compares CSPC Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $195,650,407,333
Average return on equity (ROE) among peers: 13.91%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
CSPC Pharmaceutical Group Limited (CVG)	€34.55 Billion	13.05%	0.35x	$9.80 Billion
Bayer AG NA (BAYN)	$47.52 Billion	8.61%	1.66x	$36.43 Billion
Cosmo Pharmaceuticals N.V (C43)	$463.79 Million	3.71%	0.64x	$1.51 Billion
CSPC PHARMACEUT.GR. ADR4 (CVGU)	$31.64 Billion	19.25%	0.32x	$11.04 Billion
GRIFOLS ADR 1/2/EO-50 (G0F)	$8.61 Billion	1.82%	1.49x	$4.21 Billion
Grifols S.A (G0FB)	$3.73 Billion	14.63%	1.72x	$4.42 Billion
GSK PLC SP. ADR/2 NEW (GS70)	$12.79 Billion	38.52%	3.61x	$101.34 Billion
ORION CORP.B UNSP.ADR 1/2 (OFK0)	$1.00 Billion	32.83%	0.62x	$8.31 Billion
Sanofi (SNW2)	$59.11 Billion	4.75%	0.91x	$105.07 Billion
ASTELLAS PHARMA UNSP.ADR (YPHA)	$1.60 Trillion	1.07%	1.24x	$19.55 Billion

About CSPC Pharmaceutical Group Limited

F:CVG Germany Drug Manufacturers - General

Market Cap

$9.80 Billion

€8.38 Billion EUR

Market Cap Rank

#2302 Global

#470 in Germany

Share Price

€0.73

Change (1 day)

-1.09%

52-Week Range

€0.73 - €1.25

All Time High

€1.25